Last updated: May 26, 2026
Suppliers for MIRVASO (brimonidine) in the US and EU: Who makes it, what they supply, and how supply risk shows up in drug labels
MIRVASO is brimonidine topical for rosacea. Supplier coverage for finished product and key raw materials is determined by (1) the US FDA label/manufacturing sections, (2) the application and marketing authorizations tied to the label holder, and (3) public drug substance and contract manufacturing disclosures in regulatory filings and industry databases.
Result: no complete, source-backed supplier roster (finished product manufacturers, labeled sites, and brimonidine/drug-substance suppliers) can be produced from the information provided in this prompt.
What manufacturers supply MIRVASO (brimonidine) finished product in the US?
Featured answer: The supplier identity for MIRVASO finished product must come from the US FDA label “Manufactured for / Manufactured by” and related manufacturing sections. Without those label fields, no accurate supplier list can be compiled.
Which label sections list MIRVASO manufacturing sites?
- “Manufactured for” and “Manufactured by” statements on the current US FDA prescribing information
- “Distributed by” and repackager language if present
- Strength and dosage-form-specific manufacturing statements (topical solution vs gel)
Which drug substance suppliers make brimonidine for MIRVASO?
Featured answer: Brimonidine drug substance suppliers cannot be reliably inferred from MIRVASO marketing without access to DMF-linked data, supplier letters, or validated regulatory disclosures.
What sources normally identify brimonidine drug substance suppliers?
- DMF (Drug Master File) public acknowledgements connected to the reference listed drug
- EU ASMF/CEP-linked manufacturer names for brimonidine
- Contract manufacturing disclosures in regulatory updates
What contract manufacturing organizations (CMOs) supply MIRVASO batches?
Featured answer: CMO identity depends on site-specific “Manufactured by” listings on the drug label and any listed manufacturing sites in FDA registration data. Those exact data are not present in the prompt.
How to map CMO supply risk to MIRVASO
- Count the number of distinct manufacturing sites listed on the label
- Track manufacturing site changes via label revisions
- Compare manufacturing site language between label versions across years
How many suppliers exist for MIRVASO and how concentrated is supply?
Featured answer: The number of MIRVASO suppliers is label- and database-dependent. Without label manufacturing site data, concentration cannot be quantified.
Supply concentration metrics used in diligence
- Share of batches from single site (if available from CGT/COA distribution, not provided)
- Single-point-of-failure risk from one API site or one fill-finish site
- Ability to qualify alternate sites under cGMP within defined time windows
What raw material constraints affect MIRVASO supply (brimonidine API, solvents, excipients)?
Featured answer: Raw-material risk depends on sourcing of brimonidine and specialized topical excipient systems (solvents, pH modifiers, film-formers/penetration enhancers if used in the dosage form). Supplier names and qualification status are not available in the prompt.
Where raw material supply risk is documented
- DMF letters and supplier qualification summaries (not provided)
- FDA manufacturing process change supplements referencing critical suppliers (not provided)
Which companies control MIRVASO quality and regulatory filings in the US?
Featured answer: The company controlling quality and regulatory filings is the label holder and its responsible manufacturing entities. That mapping requires the current US label and listing data.
Typical ownership mapping
- Label holder (applicant/marketing authorization holder)
- Responsible QP/manufacturer for EU
- API holder (often via DMF holder, if distinct)
What is the Orange Book status of MIRVASO and does it indicate supplier structure?
Featured answer: Orange Book listings indicate reference product and patent/RLD status, not supplier identities. Supplier identity requires label manufacturing sections and regulatory site listings.
How exclusivity and listing status affect supply contracting
- Sole source dynamics are more likely when there is limited generic competition
- Supply branching often increases with formulation or dosage-form alternatives (not established here)
What patent or litigation signals restrict supplier substitution for MIRVASO?
Featured answer: Patent status affects market entry, not necessarily who manufactures the branded product. Without the MIRVASO patent estate and litigation record in scope, no constraint analysis can be produced.
Litigation-driven supplier barriers usually show up as
- Settlement terms that restrict supply chain changes by entrants (not provided)
- Injunctions targeting manufacturing method or finished formulation (not provided)
How does MIRVASO compare with other brimonidine topical products in supplier patterns?
Featured answer: Comparison requires identifying alternative brimonidine-topical products and their label manufacturing sites. Those label datasets are not provided.
What to compare across products
- Number of listed manufacturing sites
- Whether API and fill-finish are co-located
- Regional manufacturing differences (US vs EU)
Key Takeaways
No complete, source-backed supplier roster for MIRVASO (finished product manufacturers, brimonidine API suppliers, and CMOs) can be produced from the prompt alone. Supplier identification requires the current MIRVASO label manufacturing sections and regulatory site disclosures, which are not present here.
FAQs
- Who is the manufacturer listed on the MIRVASO US label?
- Which companies supply brimonidine API for MIRVASO?
- Are there multiple MIRVASO manufacturing sites or a single source?
- Does MIRVASO have EU manufacturing listed with a QP release site?
- Do MIRVASO supplier changes appear in label revision history?
References (APA)
- US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Website).
- US FDA. Drugs@FDA. (Website).
- European Medicines Agency. EPAR and product information for brimonidine-containing products. (Website).
